Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | MERTK | Q12866 | 2/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.39 |
| ▸ | AXL | P30530 | 2/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5453421 | 0.91 | MERTK (0.45) | KDRMERTKCSNK1DMAPK14AXL | |
| SCHEMBL5449738 | 0.89 | KDR (0.46) | KDRMERTKCSNK1DMAPK14AXL | |
| SCHEMBL5451180 | 0.88 | KDR (0.49) | KDRMERTKCSNK1DMAPK14AXL | |
| SCHEMBL5449793 | 0.86 | KDR (0.46) | KDRMERTKCSNK1DMAPK14AXL | |
| SCHEMBL6106623 | 0.86 | TP53 (0.45) | KDRMAPK14CDK4MAPK10 | |
| SCHEMBL6107167 | 0.86 | TP53 (0.45) | KDRMAPK14CDK4MAPK10 | |
| SCHEMBL6106982 | 0.85 | TP53 (0.46) | KDRCSNK1DCDK4MAPK10 | |
| SCHEMBL5456838 | 0.84 | CSNK1D (0.51) | CSNK1DMAPK14CDK4MAPK10 | |
| SCHEMBL5462491 | 0.84 | CSNK1D (0.51) | CSNK1DMAPK14CDK4MAPK10 | |
| SCHEMBL6105297 | 0.84 | CDK4 (0.47) | KDRCSNK1DMAPK14CDK4MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7153855-B2 | Pyrazolopyridinyl pyrimidine therapeutic compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-26 | — | — | US | disclosed |
| US-20050049260-A1 | Therapeutic compounds | SMITHKLINE BEECHAM CORPORATION | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049260-A1 | Therapeutic compounds | ABCB1, PCSK9, ABCB11 | KDR 4025/4885MERTK 3802/4885CSNK1D 573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.